52025-39-5

Basic information

• Product Name: N2-ethylpyridine-2,5-diamine
• Synonyms: N2-ethylpyridine-2,5-diamine;2-Ethylamino-5-pyridinamine;Einecs 257-614-9;N2-ethyl-2,5-Pyridinediamine
• CAS NO: 52025-39-5
• Molecular Formula: C7H11N3
• Molecular Weight: 137.18234
• EINECS: 257-614-9
• Mol File: 52025-39-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 313.7°C at 760 mmHg
• Flash Point: 143.5°C
• Appearance: /
• Density: 1.134g/cm³
• Vapor Pressure: 0.000488mmHg at 25°C
• Refractive Index: 1.626
• CAS DataBase Reference: N2-ethylpyridine-2,5-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N2-ethylpyridine-2,5-diamine(52025-39-5)
• EPA Substance Registry System: N2-ethylpyridine-2,5-diamine(52025-39-5)

Safety Data

• Hazardous Substances Data: 52025-39-5(Hazardous Substances Data)

Usage

General Description

N2-ethylpyridine-2,5-diamine, also known as 2,5-diethylnicotinamide, is a chemical compound with the molecular formula C10H15N3. It is a derivative of nicotinamide, a vitamin B3 compound, and is used in the synthesis of pharmaceuticals and organic compounds. N2-ethylpyridine-2,5-diamine has potential applications in the development of drugs for cancer and neurodegenerative diseases. The compound is also being studied for its potential antioxidant and anti-inflammatory properties. N2-ethylpyridine-2,5-diamine is an important building block in the field of medicinal chemistry and drug discovery.

InChI:InChI=1/C7H11N3/c1-2-9-7-4-3-6(8)5-10-7/h3-5H,2,8H2,1H3,(H,9,10)

Upstream product

• 67730-09-0 2-(N-ethylamino)-5-nitropyridine 
• 37059-57-7 2-(ethylamino)pyridine 

Relevant articles and documents

α2-adrenoceptor antagonists: Synthesis, pharmacological evaluation, and molecular modeling investigation of pyridinoguanidine, pyridino-2-aminoimidazoline and their derivatives

We have previously identified phenylguanidine and phenyl-2-aminoimidazoline compounds as high affinity ligands with conflicting functional activity at the α2-adrenoceptor, a G-protein-coupled receptor with relevance in several neuropsychiatric conditions. In this paper we describe the design, synthesis, and pharmacological evaluation of a new series of pyridine derivatives [para substituted 2- and 3-guanidino and 2- and 3-(2-aminoimidazolino)pyridines, disubstituted 2-guanidinopyridines and N-substituted-2-amino-1,4-dihydroquinazolines] that were found to be antagonists/inverse agonists of the α2-adrenoceptor. Furthermore, the compounds exert their effects at the α2-adrenoceptor both in vitro in human prefrontal cortex tissue and in vivo in rat brain as shown by microdialysis experiments. We also provide a docking study at the α2A- and α2C-adrenoceptor subtypes demonstrating the structural features required for high affinity binding to the receptor.

THIAZOLIDINONES, PRODUCTION AND USE THEREOF AS MEDICAMENTS

-